Market research
NGEN.V NervGen Pharma Corp
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 408M
- P/E ratio
- Not available
- Analyst target
- 7.4833
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA64082X2032
- Market cap
- 408M
- P/E ratio
- Not available
- Analyst target
- 7.4833
- Dividend yield
- Not available
- Beta
- 0.86
About
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NGEN.V discussion.
5 years, 5 months ago
NervGen Pharma Corp is currently in a long term downtrend where the price is trading 6.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
NervGen Pharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 8.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.0% to $-1M since the same quarter in the previous year.
Based on the above factors, NervGen Pharma Corp gets an overall score of 3/5.